Home › Encyclopedia › Anamorelin: Investigational Compound Overview
Research / Unapproved

Anamorelin: Investigational Compound Overview

Drafted by an automated content engine from FDA, PubChem, ClinicalTrials.gov, NIH DSLD, and Open Beauty Facts data.

Molecular formulaC31H42N6O3
Molecular weight546.7 g/mol
Registered trials11
PubChem CID9828911

Key takeaways

  • Anamorelin is an investigational compound and does not have an FDA-approved label.
  • It has been studied in the context of cancer-related weight loss and fatigue.
  • Eleven trials involving anamorelin are registered.
  • Some trials have reached completion while others were terminated or remain active without recruiting.

What anamorelin is

Anamorelin is a small molecule compound with the formula C31H42N6O3 and a molecular weight of approximately 546.7. It is cataloged under PubChem CID 9828911. No approved drug label currently exists for anamorelin, so there is no FDA-recognized indication, mechanism statement, or brand name to report.

Trial footprint

Eleven clinical trials involving anamorelin have been registered. Among the sampled studies, one Phase 2 trial in advanced pancreatic cancer was terminated, while a Phase 2 study examining anamorelin alongside physical activity and nutritional counseling for cancer-related fatigue remains active but is not recruiting. A separate trial evaluating anamorelin hydrochloride for weight loss and anorexia associated with advanced non-small cell lung cancer reached completion. These studies reflect the range of research interest in anamorelin without indicating any established clinical benefit.

FAQ

Is anamorelin FDA approved?
No. Anamorelin does not have an FDA-approved label. It remains an investigational compound studied in clinical research settings.
What is anamorelin being studied for?
Registered trials have examined anamorelin in contexts such as cancer-related weight loss, anorexia, and fatigue in patients with advanced tumors. These are research studies and do not establish an approved use.
How many clinical trials have studied anamorelin?
Eleven clinical trials involving anamorelin are registered. Their statuses range from completed to terminated to active without recruiting.
What happened in the anamorelin pancreatic cancer trial?
A Phase 2 study of anamorelin in advanced pancreatic cancer was terminated. Details on the specific reason for termination are not part of the available trial summary.
Is there safety data available for anamorelin?
No adverse event report data was available for anamorelin at this time. This does not confirm the absence of side effects, only that reporting data was not accessible for this summary.
This page is an editorial information resource. It does not sell, prescribe, or recommend any medication. Content is editorial information, not medical advice. Talk to your doctor before any treatment decision.

Sources: ClinicalTrials.gov PubChem

Updated 2026-08-04